Abstract
VCP/p97/Cdc48, a member of the ATPases associated with diverse cellular activities (AAA) family, is necessary for the endoplasmic-reticulum-associated protein degradation (ERAD) pathway to maintain protein homeostasis. Overwhelming proteotoxic stress drove cancer cells to enhance VCP/p97/Cdc48-associated ERAD to maintain protein homeostasis for survival, demonstrating that VCP/p97/Cdc48 expression was positively correlated with cancer prognosis. More studies revealed that targeting VCP/p97/Cdc48 could be a potential target in cancer therapy. CB-5083, a novel inhibitor of VCP/p97/Cdc48, is in clinical trials as the first VCP/p97/Cdc48- inhibiting drug for cancer therapy. Here, we discuss the relationship between VCP/p97/Cdc48, ERAD, protein homeostasis and cancer therapy.
Keywords: VCP/p97/Cdc48, protein homeostasis, ERAD, cancer therapy, ER stress, CB-5083.
Current Molecular Medicine
Title:VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy
Volume: 17 Issue: 9
Author(s): B. Lan, S. Chai, P. Wang*K. Wang*
Affiliation:
- Department of Respiratory Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou,China
- Department of Respiratory Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou,China
Keywords: VCP/p97/Cdc48, protein homeostasis, ERAD, cancer therapy, ER stress, CB-5083.
Abstract: VCP/p97/Cdc48, a member of the ATPases associated with diverse cellular activities (AAA) family, is necessary for the endoplasmic-reticulum-associated protein degradation (ERAD) pathway to maintain protein homeostasis. Overwhelming proteotoxic stress drove cancer cells to enhance VCP/p97/Cdc48-associated ERAD to maintain protein homeostasis for survival, demonstrating that VCP/p97/Cdc48 expression was positively correlated with cancer prognosis. More studies revealed that targeting VCP/p97/Cdc48 could be a potential target in cancer therapy. CB-5083, a novel inhibitor of VCP/p97/Cdc48, is in clinical trials as the first VCP/p97/Cdc48- inhibiting drug for cancer therapy. Here, we discuss the relationship between VCP/p97/Cdc48, ERAD, protein homeostasis and cancer therapy.
Export Options
About this article
Cite this article as:
Lan B., Chai S. , Wang P. *, Wang K.*, VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy, Current Molecular Medicine 2017; 17 (9) . https://dx.doi.org/10.2174/1566524018666180308111238
DOI https://dx.doi.org/10.2174/1566524018666180308111238 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Establishing Genomic/Transcriptomic Links Between Alzheimer’s Disease and Type 2 Diabetes Mellitus by Meta-Analysis Approach
CNS & Neurological Disorders - Drug Targets De Novo Malignancies After Organ Transplantation: Focus on Viral Infections
Current Molecular Medicine Chemoprevention of Skin Carcinomas in High-Risk Transplant Recipients
Current Medicinal Chemistry Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets Pharmacogenomics in Colorectal Cancer
Current Pharmacogenomics Effects of Estrogen in the Brain: Is it a Neuroprotective Agent in Alzheimers Disease?
Current Aging Science Synthesis of Quinazolines as Tyrosine Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Biologically Active Selenophenes and Benzo[b]selenophenes
Current Organic Synthesis Circadian Rhythm in Cytokines Administration
Mini-Reviews in Medicinal Chemistry OX40 and OX40L Interaction in Cancer
Current Medicinal Chemistry Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Application of Radiolabeled Antibodies in Targeting Therapy of Breast Cancer
Current Molecular Imaging (Discontinued) Radiopharmaceuticals Labelled with Copper Radionuclides: Clinical Results in Human Beings
Current Radiopharmaceuticals Combination of Anti-EGFR Drugs with Anti-Angiogenic or Other Signal Transduction Inhibitors as a Rational Approach to Cancer Therapy
Current Cancer Therapy Reviews Clinical Aspects of Clara Cell 10-kDa Protein / Uteroglobin (Secretoglobin 1A1)
Current Pharmaceutical Design Long Non-Coding RNA: An Emerging Paradigm of Pancreatic Cancer
Current Molecular Medicine Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews Protein kinases and the Hypoxia-Inducible Factor-1, two switches in angiogenesis
Current Pharmaceutical Design Overcoming the Drug Resistance Problem with Second-Generation Tyrosine Kinase Inhibitors: From Enzymology to Structural Models
Current Medicinal Chemistry A Novel Marine Drug, SZ–685C, Induces Apoptosis of MMQ Pituitary Tumor Cells by Downregulating miR–200c
Current Medicinal Chemistry